Form 10-Q - Quarterly report [Sections 13 or 15(d)]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2023

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 000-55000

EARTH SCIENCE TECH, INC.

(Exact name of registrant as specified in its charter)

Florida

80-0931484

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

8950 SW 74^th CT

Suite 101

Miami, FL 33156

(Address of principal executive offices) (zip code)

(305) 724-5684

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.001 par value		ETST		Over the Counter Bulletin Board

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of December 31, 2023, there were 314,850,730 Common and 1,000,000 Preferred shares of the registrant’s stock outstanding.

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION

ITEM 1.	Financial Statements (Unaudited)	F-1
	Consolidated Balance Sheets	F-1
	Consolidated Statements of Operations	F-2
	Consolidated Statements of Changes in Shareholders’ Equity	F-3
	Consolidated Statements of Cash Flows	F-4
	Notes to Consolidated Financial Statements	F-5-F-14
ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	8
ITEM 4.	Controls and Procedures	8

PART II. OTHER INFORMATION

ITEM 1.	Legal Proceedings	9
ITEM 1A.	Risk Factors	9
ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	9
ITEM 3.	Defaults Upon Senior Securities	9
ITEM 4.	Mine Safety Disclosures	9
ITEM 5.	Other Information	9
ITEM 6.	Exhibits	9

SIGNATURES		10

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Earth Science Tech, Inc. & Subsidiaries

Consolidated Balance Sheets

	December 31, 2023			March 31, 2023
ASSETS
Current Assets:
Cash	$	205,718		$	35,756
Accounts Receivable (net allowance of $0 and $0 respectively)	$	112,826		$	0
Inventory	$	395,483		$	10,260
Total current assets		714,027			46,016

Other Assets:
Property and Equipment, net	$	121,339		$	143,213
Right of use asset, net	$	123,491		$	200,674
Intangible assets, net	$	122,318		$	137,819
Goodwill	$	2,164,480		$	2,164,480
Total other assets		2,531,628		$	2,646,186
Total Assets	$	3,245,655		$	2,692,202

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable and accrued liabilities	$	643,434		$	517,137
Current portion of loans and obligations	$	30,492		$	604,767
Other Payables - Equipment Leases	$	68,050		$	117,193
Interest Payable	$	15,006		$	0
Current portion of operating lease obligations	$	68,184		$	68,188
Total current liabilities		825,166		$	1,307,285
Operating lease obligations; less current maturities	$	45,606		$	96,743
Loans and obligations; less current maturities	$	215,500		$	204,408
Total Liabilities	$	1,086,272		$	1,608,436
Stockholders’ (Deficit) Equity:
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 0 shares issued and outstanding as of December 31, 2023, and March 31, 2023, respectively	$	1,000		$	1,000
Common stock, par value $0.001 per share, 750,000,000 shares authorized; 314,850,730 and 282,612,083 shares issued and outstanding as of December 31, 2023, and March 31, 2023 respectively	$	314,852		$	282,612
Additional paid-in capital		31,766,199		$	31,303,138
Accumulated deficit		(29,922,668	)	$	(30,502,984	)
Total stockholders’ (Deficit)Equity	$	2,159,383		$	1,083,766
Total Liabilities and Stockholders’ (Deficit) Equity	$	3,245,655		$	2,692,202

F-1

Earth Science Tech, Inc. & Subsidiaries

Consolidated Statements of Operations

	2023			2022			2023			2022
	For the Three Months Ended December 31,						For the Nine Months Ended December 31,
	2023			2022			2023			2022
Revenue	$	3,790,112		$	2,533		$	5,937,766		$	2,533
Cost of revenues		1,413,414			825			2,230,805			825
Gross Profit		2,376,698			1,708			3,706,961			1,708

Operating Expenses:

Compensation - officers		389,274			9,654			467,545			86,173
Officer compensation stock		0			0			0			4,500
Compensation – staff		181,524			0			361,558			0
General and administrative		1,496,708			5,599			2,012,669			161,540
Professional fees		27,135			22,233			97,181			31,433
Amortization & Depreciation		47,964			0			114,558			0
Marketing		3,062			4,200			19,586			4,200
Litigation Expense		0			0			0			512,725
Cost of legal proceedings		0			8,297			0			18,497
Total operating expenses		2,145,667			49,983			3,073,096			819,068

Income//(Loss) from operations		231,031			(48,275	)		633,864			(817,360	)
Other Income (Expenses)
Other Income		8,250			166,037			7,798			724,062
Interest expense		(13,838	)		(18,321	)		(61,347	)		(29,565	)
Note Payable Interest		0			0			0			(1,104	)
Interest SBA Loan		0			(977	)		0			(5,929	)
Total other income (expenses)		(5,588	)		146,739			(53,549	)		687,464

Net Profit/(Loss) before income taxes		225,443			98,464			580,315			(129,896	)

Income taxes		0			0			0			0

Net Profit/(Loss)	$	225,443		$	98,464		$	580,315		$	(129,896	)

F-2

Earth Science Tech, Inc. & Subsidiaries

Consolidated Statements of Stockholders’ (Deficit) Equity

For Fiscal Quarter Ended December 31, 2023

Description	Shares		Amount		Shares		Amount		Capital		Deficit			Total
	Common Stock				Preferred Stock				Additional Paid-in		Accumulated
Description	Shares		Amount		Shares		Amount		Capital		Deficit			Total

Balance at September 30, 2023		314,550,730	$	314,552		1,000,000	$	1,000	$	31,766,199	$	(30,148,111	)	$	1,933,640

Common stock issued for cash
Common stock issued for services		300,000		300											300
Common stock issued for Conversion on Note
Net Profit/(Loss)								-		-		225,443			225,443

Balance at December 31, 2023		314,850,730	$	314,852		1,000,000	$	1,000	$	31,766,199	$	(29,915,885	)	$	2,159,383

Earth Science Tech, Inc. & Subsidiaries

Consolidated Statements of Stockholders’ (Deficit) Equity

For Nine Months Ended December 31, 2023

	Common Stock				Preferred Stock				Additional Paid-in		Accumulated
Description	Shares		Amount		Shares		Amount		Capital		Deficit			Total

Balance at March 31, 2023		282,611,083	$	282,612		1,000,000	$	1,000	$	31,303,138	$	(30,502,984	)	$	1,083,766
Balance		282,611,083	$	282,612		1,000,000	$	1,000	$	31,303,138	$	(30,502,984	)	$	1,083,766

Common stock issued for cash		18,533,334		18,534						91,467					110,001
Common stock issued for services		300,000		300											300
Common stock issued for Conversion on Note		13,406,313		13,406						371,594					385,000
Net Profit/(Loss)								-				580,315			580,315

Balance at December 31, 2023		314,850,730	$	314,852		1,000,000	$	1,000	$	31,766,199	$	(29,915,885	)	$	2,159,383
Balance		314,850,730	$	314,852		1,000,000	$	1,000	$	31,766,199	$	(29,915,885	)	$	2,159,383

F-3

Earth Science Tech, Inc. & Subsidiaries

Consolidated Statements of Cash Flows

	2023			2022
	For the Nine Months Ended December 31,
	2023			2022
Cash flows from operating activities:
Net Profit/(Loss)		580,315			(129,896	)
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation		300			-
Gain on payable settlement
Depreciation and amortization		114,558			-

Changes in operating assets and liabilities:
Deposits		-			-
Increase in Accounts receivable		(112,826	)		(397,039	)
Prepaid expenses and other current assets		-			-
Inventory		(385,223	)		-
Stock issued for debt settlement					724,124
Other current liabilities		35,000			-
Accrued settlement		(310,947	)		(565,663	)
Accounts payable and accrued expenses		437,244			(300,780	)
Net cash provided in operating activities		358,421			(669,254	)

Cash flows from investing activities:
Purchases of property and equipment		-			-
Net cash used in investing activities		-			-

Cash flows from financing activities:
Proceeds from issuance of common stock		18,534			316,500
Proceeds from Additional Paid In Capital		91,467			-
Increase/(Decrease) in Loans		(213,183	)		-
Increase/(Decrease) in Other Payables		(34,136	)		-
Increase/(Decrease) in Lease Liability		(51,141	)		-
Proceeds from loans and notes		-			350,000
Net Cash Provided/Used by Financing Activities		(188,460	)		666,500
Net increase (decrease) in cash and cash equivalents		169,962			(2,754	)
Cash and cash equivalents at beginning of the period		35,756			26,942
Cash and cash equivalents at end of the period		205,718			24,188

Non-Cash Transactions
Common stock issued on conversion of notes payable		-

F-4

EARTH SCIENCE TECH, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023

(UNAUDITED)

Note 1 — Organization and Nature of Operations

Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010, subsequently changed to the State of Florida on June 27, 2022. As of November 8, 2022, the Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompoundStore.com, LLC. (“RxCompound”), Peaks Curative, LLC. (“Peaks”), and Earth Science Foundation, Inc. (“ESF”).

RxCompound is a complete compounding pharmacy. Rx Compound Currently licensed to fulfill prescriptions in the states of Arizona, Colorado, Delaware, Florida, Georgia, Iowa, Maryland, Minnesota, Missouri, New York, New Jersey, Nevada, North Carolina, Ohio, Pennsylvania, Rhode Island, Utah, Washington, and Wisconsin. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to fulfill prescriptions.

Peaks is a telemedicine referral site focused on men’s health. Peaks’ orders are exclusively fulfilled by RxCompound. Patients who order Peaks via monthly subscription receive their refills automatically. Currently, Peaks is focused on Men’s health, and, more specifically, ED. The company intends to expand offerings to include over the counter (“OTC”) (non-prescription) products such as supplements and topicals. The OTC products will be custom manufactured or fulfilled through partnered companies under the Peaks brand and offered worldwide.

ESF is a favored entity of ETST, effectively being a non-profit organization that was incorporated on February 11, 2019, and is structured to accept grants and donations to help those in need of assistance in paying for prescriptions.

Note 2 — Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).

Principles of consolidation

The accompanying consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries RxCompound, Peaks Curative, and ESF.

The Company’s acquisition of RxCompound was consummated on November 8, 2022, along with Peaks Curative; however, RxCompound completed its PCAOB audit on February 3, 2023 (“Acquisition Date”). Operating results of subsidiaries have been consolidated according to their acquisition dates. No intercompany transactions and balances were identified.

Use of estimates and assumptions

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas requiring significant estimates are impairment of goodwill, provision for taxation, accrued liabilities, liabilities for legal matters, the determination of useful lives of depreciable and intangible assets, contingencies, and going concern assessment. The estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from those estimates.

F-5

Carrying value, recoverability, and impairment of long-lived assets

Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC’) 360 to evaluate its long-lived assets. The Company’s long-lived assets, which include property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.

The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.

The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events. Impairment of assets, if any, are included in operating expenses.

Cash and cash equivalents

Cash and cash equivalents include all highly liquid debt instruments with original maturities of three months or less which are not securing any corporate obligations. As of December 31, 2023, and March 31, 2023, the Company held a cash balance of $205,718 and $35,756, respectively.

Related parties

The Company follows ASC 850 for the identification of related parties and disclosure of related party transactions.

Pursuant to this ASC related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

Commitments and contingencies

The Company follows ASC 450 to account for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

F-6

Revenue recognition

Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.

Inventories

The Company has its inventories stated at the lower of cost (on first in, first out (FIFO) method) or market value basis. A reserve is established if necessary to reduce excess or obsolete inventories to their realizable value. The stated cost consists of bulk ingredients used to compound finished products as well as finished products. Reserves, if necessary, are recorded to reduce inventory to market value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated annually and are based on the Company’s business plan and from feedback from customers and the product development team.

Cost of Revenues

Components of costs of sales include product and shipping costs to customers and any inventory adjustments.

Shipping and Handling Costs

The Company accounts shipping and handling costs to customers as cost of revenue.

Research and development

Research and development costs are expensed as incurred. The Company’s research and development expenses relate to its engineering activities, which consist of the design and development of new products for specific customers, as well as the design and engineering of new or redesigned products for the industry in general.

Income taxes

The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. This first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.

The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2023, the Company has not recorded any unrecognized tax benefits.

F-7

Interest and penalties related to liabilities for uncertain tax positions will be charged to interest and operating expenses, respectively. The Company has net operating loss carryforwards (NOL) for income tax purposes of approximately $1,600,281. This loss is allowed to be offset against future income until the year 2039 when the NOL’s will expire. The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the substantial losses incurred through March 31, 2022. The change in the valuation allowance for the six months ended December 31, 2023, and 2022, was an increase of $0 and $0, respectively.

Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. The Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013 and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes are limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income after the ownership change.

Net loss per common share

The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the year. Diluted loss per common share calculations is determined by dividing net results from operations by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

For the nine months ended December 31, 2023, shares issuable upon conversion of convertible notes were anti-dilutive. As such, their effect has not been included in the calculation of diluted net loss per share. No dilutive common shares in the comparative year.

Cash flows reporting

The Company follows ASC 230 to report cash flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by this standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports separately information about investing and financing activities not resulting in cash receipts or payments in the period pursuant this standard.

Goodwill

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Goodwill is reviewed for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. In conducting its annual impairment test, the Company first reviews qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If factors indicate that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment and the fair value of the reporting unit is determined by analyzing the expected present value of future cash flows. If the carrying value of the reporting unit continues to exceed its fair value, the fair value of the reporting unit’s goodwill is calculated and an impairment loss equal to the excess is recorded. As of December 31, 2023, the Company recognized goodwill on the acquisition of its wholly owned subsidiaries; RxCompound and Peaks.

Stock based compensation

The Company applies the fair value method of ASC 718, Compensation-Stock Compensation, in accounting for its stock-based compensation. These standards state that compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period, if any. The Company uses the Black-Scholes option pricing model to determine the fair value of its stock, stock option and warrant issuance. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a few complex and subjective variables. These variables include the Company’s expected stock price, volatility over the term of the awards, actual employee exercise behaviors, risk-free interest rate and expected dividends. The company has no stock-based commitments outstanding as of December 31, 2023, and 2022.

F-8

Fair Value

FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories:

Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs;

Level 2 — Significant other observable inputs that can be corroborated by observable market data; and

Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data.

The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items.

The fair value of the Company’s debt approximated the carrying value of the Company’s debt as of December 31, 2023, and December 31, 2022. Factors that the Company considered when estimating the fair value of its debt included market conditions, liquidity levels in the private placement market, variability in pricing from multiple lenders and terms of debt.

Property and equipment

Property and equipment are stated at cost net of accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation on equipment is charged using a straight-line method over the estimated useful life of 5 years.

Recently issued accounting pronouncements

We have considered the impact of the following pronouncements:

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective January 1, 2023, and will apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 did not have an impact on the Company’s consolidated financial statements because the Company did not acquire a business during the three and nine months ended December 31, 2023.

The FASB recently issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, which requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities for fiscal years beginning after December 15, 2021, with early adoption permitted (for “emerging growth companies” beginning after December 15, 2023). The Company has assessed the impact this standard will have on the Company’s consolidated financial statements. No material adjustments were required.

F-9

Intangible Assets

Intangible assets consist of Peaks telemedicine property, the Company’s web properties and goodwill recognized by RxCompound which is presented on the historical basis at date of acquisition by the Company. Prior to the acquisition, RxCompound, elected to amortize goodwill as an intangible asset on a straight-line basis over 10 years. All other Intangible assets with finite lives are amortized over the estimated useful life of five years. These assets are evaluated for impairment at least on an annual basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We assess recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.

Reclassification

No restatement was made in comparative Consolidated Financial Statements. However, certain amounts from the prior year have been reclassified to conform to the current year presentation.

Note 3 — Going Concern

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. On December 31, 2023, the Company had negative working capital, an accumulated deficit of $29,922,668. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company as of November 8, 2022, became a holding entity set to acquire companies with its recent two acquisitions, RxCompound and Peaks both operating in the health and wellness industry. The Company’s cash position may not be sufficient to pay its obligations and support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate sufficient revenues may provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate sufficient revenues by acquiring companies and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenues.

The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 4 - Related Party Balances and Transactions

Parties are considered to be related if one party has the ability to control or exercise significant influence over the other party in making financial and operating decisions. Transactions with related parties have been disclosed in debt, acquisition, and officer’s compensation notes. As of December 31, 2023, the Company had no related party balances.

Note 5 – Stockholders’ Equity

During the three months ended December 31, 2023, and 2022, the Company issued 300,000 shares and 62,600,000 shares of restricted common stock for cash of $0 and $316,500 respectively, (see ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS).

During the three months ended December 31, 2023, and 2022, the Company issued 0 shares and 136,312,440 shares of restricted common stock for debt settlements at a fair value of $0 and $724,124 respectively, (see RESULTS OF OPERATIONS and ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS).

On November 28, 2023, the Company” amended its Articles Incorporation (the “Amendment’) in the State of Florida to reduce its Authorized Shares of Common Stock from 750,000,000 shares to 350,000,000 shares. The Amendment was through a voting majority Shareholder Written Consent and a Corporate Resolution. The Amendment was stamped and uploaded by the State of Florida on January 8, 2024

F-10

Note 6 — Commitments and Contingencies

Legal Proceedings

From time to time and in the course of business, we may become involved in various legal proceedings seeking monetary damages and other relief. The amount of the ultimate liability, if any, from such claims cannot be determined. As of the date hereof, there are no legal claims currently pending or, to our knowledge, threatened against us or any of our officers or directors in their capacity as such or against any of our properties that, in the opinion of our management, would be likely to have a material adverse effect on our financial position, results of operations or cash flows.

Employment and Consulting Agreements

The Company has entered into amended employment agreements with the current CEO, Giorgio R. Saumat, and President, Mario G. Tabraue. The amended term of the employment agreements commenced on October 1, 2023, for a term of twelve months. The Executive compensation is 21% and 10.5% of monthly revenue, respectively. Compensation is payable the first day of the month for the preceding month’s revenue so long as the company increases its cash position quarter over quarter. In the event the Company does not increase its cash position, the arrangement must be renegotiated, and there will be no payment at the beginning of the new quarter. The agreements include a back pay waiver, and the Executive must waive all rights to any and all compensation, including back pay, for any and all work done on behalf of the Company prior to September 30, 2023.

On August 1, 2023, Company’s subsidiary, RX Compound, entered into an agreement with its chief pharmacist, Shibu John. Under the terms of the employment agreement Mr. John was issued 300,000 shares of Company’s restricted common stock as additional compensation.

Note 7 — Property and Equipment

Schedule of Property And Equipment

	December 31, 2023			December 31, 2022
	For the Fiscal Quarter Ended December 31,
	December 31, 2023			December 31, 2022

Equipment – cost	$	150,082		$	-
Less: Accumulated depreciation		(28,743	)		-
Property and Equipment, Net	$	121,339		$	-

Depreciation expense for the fiscal quarters ended December 31, 2023, and December 31, 2022, was $99,056 and $0, respectively.

During the fiscal quarter ended December 31, 2023, there were no additions to the Property and Equipment.

Note 8 — Leases

The Company treats a contract as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, or the Company directs the use of the asset and obtains substantially all the economic benefits of the asset. These leases are recorded as right-of-use (“ROU”) assets and lease obligation liabilities for leases with terms greater than 12 months. ROU assets represent the Company’s right to use an underlying asset for the entirety of the lease term. Lease liabilities represent the Company’s obligation to make payments over the life of the lease. A ROU asset and a lease liability are recognized at commencement of the lease based on the present value of the lease payments over the life of the lease. Initial direct costs are included as part of the ROU asset upon commencement of the lease. Since the interest rate implicit in a lease is generally not readily determinable for the operating leases, the Company uses an incremental borrowing rate to determine the present value of the lease payments. The incremental borrowing rate represents the rate of interest the Company would have to pay to borrow on a collateralized basis over a similar lease term to obtain an asset of similar value.

F-11

The Company reviews the impairment of ROU assets consistent with the approach applied for the Company’s other long-lived assets. The Company reviews the recoverability of long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company’s ability to recover the carrying value of the asset from the expected undiscounted future pre-tax cash flows of the related operations. The Company elected the practical expedient to exclude short-term leases (leases with original terms of 12 months or less) from ROU asset and lease liability accounts.

RxCompoundStore.com, LLC entered into a lease arrangement on May 26, 2022, whereby the subsidiary obtained the possession of the property located at 8950 SW 74th Court Suite 101, Miami, FL, 33156. The lease requires monthly payments of $7,057 for a term of 36-months plus the single lump sum payment of $40,000 upon execution in June 2022. The facility consists of two offices, a sterile compounding cleanroom, a cooking room, a reception area, a fulfillment area, and storage for inventory. The lease agreement does not contain any significant residual value guarantees or restrictive covenants but does contain a 3-year renewal option. The Company treated this lease arrangement as an operating lease and recognized right of use asset and lease liability accordingly.

Supplemental balance sheet information related to leases were as follows:

	2023		2022
	For the Fiscal Quarter Ended December 31,
	2023		2022

Assets
Right of use asset, net	$	123,491	$	-

Operating lease liabilities
Current		68,184		-
Non-current		45,606		-
Total Lease Liabilities	$	113,790	$	-

The components of lease cost were as follows:

Schedule of Lease Cost

	2023		2022
	For the Fiscal Quarter Ended December 31,
	2023		2022

Depreciation	$	30,873	$	-
Interest on lease obligation		3,828		-
Total lease cost	$	34,701	$	-

Note 9 — Intangible Assets

Intangible assets, consisted of the following:

Schedule of Intangible Assets

	2023			2022
	For the Fiscal Quarter Ended December 31,
	2023			2022

Telemedicine Property	$	17,806		$	17,806
Web Properties		19,323			-
Goodwill – historical basis		138,312			-
Accumulated Amortization		(53,123	)		-
Net Balance	$	122,318		$	17,806

F-12

NOTE 10- GOODWILL

Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in the business combinations. On November 08, 2022, the Company acquired 100% of the outstanding equity shares of RxCompoundStore.com, LLC and Peaks Curative, LLC against the share exchange consideration and recognized Goodwill.

SCHEDULE OF GOODWILL

	For the Fiscal Quarter Ended December 31,
	2023		2022
RxCompound and Peaks	$	2,164,480	$	-

Total	$	2,164,480	$	-

The Company has evaluated all relevant events and circumstances as of December 31, 2023, which could have a negative effect on the future expected earnings or cashflow that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset. There are no indicators of a change in legal or regulatory factors or business climate which would require Goodwill to be tested for impairment between annual testing dates.

Note 11 — Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	For the Fiscal Quarter Ended December 31, 2023

Accounts Payable (A)	$	515,337
Accrued Expenses (B)		128,097
Total	$	643,434

(A)

Accounts Payable

As of December 31, 2023, accounts payable included inventory under net 60 terms of $506,885, and other payables of $8,452.

(B)

Accrued Expenses

As of December 31, 2023, accrued expenses included accrued account management fee of $76,000, accrued payroll of $18,572 and other accrued expenses of $33,525.

F-13

Note 12 — Debts

Notes payable and loans payable consisted of the following:

Schedule of Notes and Loans Payable

		For the Nine Months Ended December 31,
Name		2023		2022

SBA Loan Payable	(1)	$	215,500	$	113,115
Revolving Promissory Note Payable (Issa Note)	(2)		0.00		250,000
Convertible Promissory Note - Strongbow	(3)		0.00		220,000
Convertible Note Payable – Irrevocable Trust			0.00		350,000
Notes payable – related parties			0.00		110,363
Accrued Settlement			0.00		158,846
Equipment Finance			98,543		-
		$	314,043	$	1,202,524

(1) SBA Loan

On July 27, 2020, the Holding Company executed a secured loan with the U.S. Small Business Administration (SBA) under the Economic Injury Disaster Loan program in the amount of $106,800. The loan is secured by all tangible and intangible assets of the Company and payable over 30 years at an interest rate of 3.75 % per annum. Installment payments, including principal and interest, totaling $521.00 monthly began twelve (12) months after the date of the Note, with the first payments applied to accumulated accrued interest.

On April 01, 2021, RxCompound executed a secured loan with the U.S. Small Business Administration (SBA) under the Economic Injury Disaster Loan program in the amount of $108,700. The loan is secured by all tangible and intangible assets of the Company and payable over 30 years at an interest rate of 3.75 % per annum. Installment payments, including principal and interest, totaling $530.00 monthly, began twelve (12) months after the date of the Note, with the first payments applied to accumulated accrued interest.

Installment payments due within a year have been classified under current liabilities.

Both notes have been fully satisfied after December 31, 2023. Please refer to footnote,13 below, Subsequent Events, for additional information.

(2) Revolving Promissory Note –

On August 31, 2021, the Company issued a revolving promissory note of $250,000 to Great Lakes Holding Group, LLC. Proceeds were received in two installments of $50,000 (Jan 28, 2022) and $200,000 (April 01, 2022), respectively. Interest is charged at the rate of 5%. Repayment of interest and principal started in September 2023 in the amount of $109,167 with a remaining balance of $160,000 that the company planned to satisfy by early 2024. As of the period ended December 31, 2023, this note has been fully satisfied.

(3) Convertible Promissory Note – Strongbow

Strongbow Advisors’ accrued settlement of $220,000 with a maturity date of May 29, 2023, was amended on the maturity date, having its payment terms rescheduled. The new terms are as follows: payment of $15,000 upon execution of amended terms, followed by a 41-month period of installment payments of $5,000, commencing from September 01, 2023. In September 2023 the Company made its first two installment payments of $5,000 each along with a pre-payment of $70,000. Under the new payment terms, the Company is entitled to a 10% discount on the outstanding principle. As of September 30, 2023, the remaining balance on this note, net of regularly scheduled payments, pre-payments and pre-payment discounts, was $118,000. As of the period ended December 31, 2023, this note has been fully satisfied.

Note 13 – Correction of Errors

During 2024, the Company discovered that the Goodwill recorded on the financial statements of RxCompound prior to being acquired by Earth Science Tech, Inc. had been erroneously amortized and improperly reported in form 10-K for the year-ended March 31, 2023. As a consequence, the total assets were understated by $13,860 and the net loss was overstated by the same amount. The Company is in the process of correcting the errors by restating each of the affected financial statement line items in the consolidated financial statements and related financial statement footnotes in an amended 10-K/A for the year-ended March 31, 2023. The error resulted in additional amortization of $10,374 for the current nine months ended December 31, 2023. The amount of the error is less than one (1) percent of revenue resulting is no material impact on the Company’s consolidated financial statements as of December 31, 2023.

Note 14 — Subsequent Events

The Company has evaluated subsequent events through February 20, 2024, which is the date the financial statements were issued, and has identified two disclosable events or transactions that took place after December 31, 2023. On January 19, 2024, RX Compound satisfied its note with the U.S. Small Business Administration (SBA) in the amount of $108,700. On February 9, 2024, the Company satisfied its note with the U.S. Small Business Administration (SBA) in the amount of $106,800.

F-14

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following section, Management’s Discussion and Analysis, should be read in conjunction with Earth Science Tech Inc.’s financial statements and the related notes thereto and contains forward-looking statements that involve risks and uncertainties, such as statements of the Company’s plans, objectives, expectations, and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect,” and the like, and/or future-tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Report on Form 10-Q. The Company’s actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of many factors. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Report filed on Form 10-Q.

The following discussion should be read in conjunction with the company’s unaudited consolidated financial statements and related notes and other financial data included elsewhere in this report. See also the notes to the Company’s consolidated financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s Registration Statement filed on Form 10-12g and the Company’s Annual Report filed on Form 10-K for the fiscal year ended March 31, 2023, as well as the Company’s Quarterly report filed on Form 10-Q for the fiscal quarter ended December 31, 2022.

OVERVIEW

The Company is a holding entity set to acquire companies with its current focus in the health and wellness industry. The Company is presently in compounding pharmaceuticals and telemedicine through its wholly owned subsidiaries RxCompound, Peaks, and ESF.

RxCompound is a compounding pharmacy that has historically focused on men’s health, specifically medical products directed at ED such as Tadalafil, and Sildenafil Citrate (the generic names for Cialis and Viagra, respectively) and longevity. RxCompound is currently licensed to fulfill prescriptions in the states of Arizona, Colorado, Delaware, Florida, Georgia, Iowa, Maryland, Minnesota, Missouri, New York, New Jersey, Nevada, North Carolina, Ohio, Pennsylvania, Rhode Island, Utah, Washington, and Wisconsin. RxCompound is in the application process to obtain licenses in the remaining states in which it is not yet licensed to dispense prescriptions. Furthermore, RxCompound recently had its sterile compounding room approved to operate in late May 2023 to provide sterile products for injection.

Peaks is the telemedicine referral site facilitating asynchronous consultations for branded compound medications prepared at RxCompound. Peaks is currently positioned to prescribe to all 50 states utilizing third-party consultation services, but only able to fulfill prescriptions within RxCompound’s licensed states. Peaks will be able to fulfill more states as RxCompound becomes licensed in additional states.

Results of Operations

The following tables set forth summarized cost of revenue information for the fiscal quarters ended December 31, 2023, and December 31, 2022:

	For the Fiscal Quarter Ended December 31,
	2023		2022

Revenue	$	3,790,112	$	2,533
Cost of revenues		1,413,414		825
Gross Profit/(Loss)		2,376,698		1,708

We had product sales of $3,790,112 and a gross profit of $2,376,698 representing a gross margin of 62.7% in the fiscal quarter ended December 31, 2023, compared with product sales of $2,533 and a gross profit of $1,708 representing a gross margin of 67.4% in the fiscal quarter ended December 31, 2022. The revenue increase in the fiscal quarter ended December 31, 2023, compared with the fiscal quarter ended December 31, 2022, is primarily due to the acquisition of RxCompound and Peaks – see Item 2 Principal of Consolidation.

For the fiscal quarter ended December 31, 2023, the Company had a gain from continuing operations of approximately $225,443 compared to a gain from continuing operations of approximately $98,464 for the fiscal quarter ended December 31, 2022. This increase in net profit is primarily due to RxCompound’s increasing volume of business.

Operating Expenses

	Fiscal Quarter Ended December 31,
	2023			2022			$ Change			% Change
Compensation – officers		389,274			9,654			379,620			3932.26	%
Officer Compensation – Stock		-			-			-			0.00	%
Compensation - Employees		181,524						181,524			100.00	%
Employee Compensation – Stock		-			-			-			0.00	%
Marketing		3,062			4,200			(1,138	)		-27.08	%
General and administrative		1,496,708			5,599			1,491,109			26631.70	%
Professional fees		27,135			22,233			4,902			22.05	%
Cost of legal proceedings		-			8,297			(8,297	)		-100.00	%
Licenses and fees		-			-			-			0.00	%
Amortization expense		9,587						9,587			0.00	%
Litigation Expense		-			-			-			0.00	%
Depreciation expense		38,377			-			38,377			100.00	%
Total operating expenses		2,145,668			49,983			2,095,685			4192.79	%

Income / (Loss) from operations		231,030			(48,275	)		279,305			-578.57	%

Other Income (Expenses):
Other income (expense)		8,250			166,037			(157,787	)		-95.03	%
Interest Income / (Expense)		(13,838	)		(19,298	)		5,460			-75.53	%
Total other income (expenses)		(5,588	)		146,739			(152,327	)		-103.8	%

Net Profit/(Loss) before income taxes		225,443			98,464			126,979			128.96	%

Income taxes		-			-			-			0.00	%

Net Profit/(Loss)		225,443			98,464			126,979			128.96	%

Marketing expenses totaled $3,062 for the fiscal quarter ended December 31, 2023, a decrease of $1,138 from $4,200 for the fiscal quarter ended December 31, 2022.

Legal fees totaled $9,825 for the fiscal quarter ended December 31, 2023, a decrease of $8,672 from $18,497 for the fiscal quarter ended December 31, 2022.This decrease is attributable to Company’s successful settlement of outstanding debts with various creditors as represented in the debt schedule detailed in Footnote 12 above.

Professional fees, exclusive of legal fees, totaled $27,135 for the fiscal quarter ended December 31, 2023, an increase of $4,902 from $22,233 for the fiscal quarter ended December 31, 2022. This increase is due to RxCompound’s hiring consultants to support marketing and order fulfillment functions as well as upgrading financial reporting capabilities.

Costs and Expenses - Costs of sales include the costs of manufacturing, packaging, warehousing, and shipping our products. As we develop and release additional products, we expect our costs of sales to increase.

General and administrative expenses, inclusive of research and development and account management fees, increased from $5,999 for the fiscal quarter ended December 31, 2022, to $1,492,651 for the fiscal quarter ended December 31, 2023. This increase is primarily attributable to the hiring of account management consultants to manage growing demand for Company’s products and corresponding increase in the number of customer accounts. Approximately 85% or 1,272,933 of the General and Administrative expenses are related to account management fees.

We are a smaller reporting company, as defined by 17 CFR § 229.10(f)(1). We do not consider the impact of inflation and changing prices as having a material effect on our net sales and revenues and on income from our operations for the previous two years or from continuing operations going forward.

Interest Expense

Interest expense for the quarter ended December 31, 2023 was 13,838, a net decrease of 11,268 compared to the quarter ended December 31, 2022 that showed interest expense of 4,483. The reduction in interest is due to Company’s successful strategy of retiring a large portion of its outstanding debt and negotiating payment discounts in the process.

Non-GAAP Financial Measures

We use Adjusted EBITDA internally to evaluate our performance and make financial and operational decisions that are presented in a manner that adjusts from their equivalent GAAP measures or that supplements the information provided by our GAAP measures. Adjusted EBITDA is defined by us as EBITDA (net income (loss) plus depreciation expense, amortization expense, interest and income tax expense, minus income tax benefit), further adjusted to exclude certain non-cash expenses and other adjustments as set forth below. We use Adjusted EBITDA because we believe it more clearly highlights trends in our business that may not otherwise be apparent when relying solely on GAAP financial measures, since Adjusted EBITDA eliminates from our results specific financial items that have less bearing on our core operating performance.

We use Adjusted EBITDA in communicating certain aspects of our results and performance, including in this Quarterly Report, and believe that Adjusted EBITDA, when viewed in conjunction with our GAAP results and the accompanying reconciliation, can provide investors with greater transparency and a greater understanding of factors affecting our financial condition and results of operations than GAAP measures alone. In addition, we believe the presentation of Adjusted EBITDA is useful to investors in making period-to-period comparison of results because the adjustments to GAAP are not reflective of our core business performance.

Adjusted EBITDA is not presented in accordance with, or as an alternative to, GAAP financial measures and may be different from non-GAAP measures used by other companies. We encourage investors to review the GAAP financial measures included in this Quarterly Report, including our consolidated financial statements, to aid in their analysis and understanding of our performance and in making comparisons.

Cash Flow & Assets

Earth Science Tech, Inc. & Subsidiaries

Consolidated Balance Sheets

	December 31, 2023			December 31, 2022
ASSETS
Current Assets:
Cash	$	205,718		$	24,188
Accounts Receivable(net allowance of $0 and $0 respectively )	$	112,826		$	0
Prepaid expenses and other current assets		0			0
Inventory	$	395,483		$	0
Total current assets		714,027			24,188

Other Assets:
Property and Equipment	$	121,339		$	0
Right of use asset, net	$	123,491		$	0
Due from RX Compound	$	0		$	397,382
Prepaid Acquisition Costs	$	0		$	98,000
Intangible assets, net	$	108,222		$	0.00
Goodwill	$	2,164,480		$	0.00
Telemedicine Platform	$	14,096		$	17,806
Total other assets		2,531,628		$	495,382
Total Assets	$	3,245,655		$	537,376

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable and accrued liabilities	$	643,434		$	235,419
Accrued Settlement – fox Rothchild	$	0		$	158,846
Current portion of loans and obligations	$	30,492		$	113,315
Issa Revolving Note	$	0		$	250,000
Accrued Settlement – Strongbow Advisors	$	0		$	220,000
Due to RXCompundStore.com., LLC	$	0		$	110,363
Convertible Mote 1 VCAMJI Irrevocable Trust	$	0		$	150,000
Convertible Mote 2 VCAMJI Irrevocable Trust	$	0		$	250,000
Other Payables	$	98,542		$	0.00
Current portion of operating lease obligations	$	0.00		$	0.00
Total current liabilities		957,476		$	1,437,943
Operating lease obligations; less current maturities	$	113,790		$	0.00
Loans and obligations; less current maturities	$	215,500		$	0.00
Total Liabilities	$	1,079,489		$	1,437,943
Stockholders’ (Deficit) Equity:
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of December 31, 2023, and December 31, 2022, respectively	$	1,000		$	1,000
Common stock, par value $0.001 per share, 750,000 shares authorized; 314,852,730 and 257,964,406 shares issued and outstanding as of December 31, 2023 and December 31, 2022 respectively	$	314,852		$	257,966
Additional paid-in capital		31,766,199		$	29,106,164
Accumulated deficit		(29,922,668	)	$	(30,265,697	)
Total stockholders’ (Deficit)Equity	$	2,159,382		$	(900,567	)
Total Liabilities and Stockholders’ (Deficit) Equity	$	3,245,655		$	537,376

A summary of our changes in cash flows & assets for the nine months ended December 31, 2023, and December, 2022, is provided below:

The Company had $205,718 in Cash for the nine months ended December 31, 2023, compared with $24,188 for the nine months ended December 31, 2022.

Assets’ position has been improved significantly with the purchase of inventory, recognition of goodwill, acquisition of equipment by RxCompound and addition of right of use assets for lease agreement of premises. Peaks also added its telemedicine platform in intangibles.

The Company had $112,826 in Accounts Receivable for the nine months ended December 31, 2023, compared with $0 for the nine months ended December 31, 2022. Accounts Receivable balance resulted from management’s decision to extend credit terms to certain of its larger customers.

The Company had $515,337 balance in Accounts Payable for the nine months ended December 31, 2023, compared with $149,236 for the nine months ended December 31, 2022. The accounts payable balance on December 31, 2023 was comprised of $506,855 in inventory under net 60 terms, and the remainder in miscellaneous payables.

Accrued expenses totaled $109,525 for the nine months ended December 31, 2023, an increase of $23,242 from $86,183 for the nine months ended December 31, 2022. The majority of the accrued expense balance on December 31, 2023 represents accrued account management fees of $76,000.

Long-term and short-term debt obligations have been reduced on settlement of outstanding claims against issue of shares.

The Company had a Stockholders Equity of $2,159,382 for the nine months ended December 31, 2023, compared with ($900,567) of Stockholders Equity for the nine months ended December 31, 2022. This improvement is primarily due to Rxcompound’s increase in total assets and revenue as well as a decrease in the Company’s total liabilities.

Cash Flow from Operating Activities

Net cash provided by operating activities for the nine months ended December 31, 2023, was $365,205 as compared to $699,254 used by the operating activities for the prior year period. The increase in cash flows from the prior year period is primarily driven by increased profitability and a decrease in cash payments related to litigation settlement agreements.

Cash Flows from Financing Activities

During the nine months ended December 31, 2023, the Company received $18,534 through the issue of common stock and $91,467 of additional paid-in-capital. During the same period, the Company used a net of $298,460 to reduce its outstanding debts.

Future Financing

As of December 31, 2023, the Company does not need any additional financing given the revenue being generated through the sales of RxCompound. If needed for expansion, the Company will seek financing with private investors through standard notes, discounted registered stock, and facilitated debt.

The Company’s Plan of Operation for the Next Twelve Months

The Company’s auditors have expressed doubt as to the Company’s ability to continue as a going concern in part, because on December 31, 2023, the Company had negative working capital and an accumulated deficit of $29,922,668.

The Company’s current liabilities have historically exceeded the Company’s Current Assets; and as of December 31, 2023,the Company’s total assets totaling $3,245,655 exceeding the Company’s liabilities of $1,086,272 by $2,159,383. In addition, the Company during the nine months ended December 31, 2023, had product sales of $5,937,766 and a gross profit of $3,706,961, representing a gross margin of 62.7%. The revenue increase is due to the acquisition of RxCompound and Peaks along with the increase in sales. This was primarily due to RxCompound’s completion of the integration of all product categories into its business, including hazardous hormonal creams and sterile injectable prescriptions. The Company recorded its highest revenue and profit generated month in December 2023. RxCompound plans to continue obtaining more accounts while expanding the states approved to fill with the capacity to compound injectables. Furthermore, the Company has been working on expanding its intellectual properties with unique platforms compared to Peaks and service providers that will further increase the Company’s assets and revenue. With this trend, the Company will have the ability to continue operating without having the need to raise capital unless needed for acquisitions or expansion.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in Company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Although the Company’s management has not formally carried out an evaluation under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”), because of the relatively thin management structure that the Company currently maintains, the Company believes that the Company’s Chief Executive Officer and Chief Financial Officer have sufficient timely information to allow them to make necessary disclosures in a timely manner.

Based on this informal evaluation, the Company’s chief executive and principal financial and accounting officer concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) were not effective as of December 31, 2023.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control and Financial Reporting

During the quarter ended December 31, 2023, the company has continued to make process improvement changes in the internal control over financial reporting which are reasonably likely to significantly improve the internal control over financial reporting. The impact of these changes made are still under evaluation as of the quarter ended December 31, 2023.

PART II — OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

The Company is a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and is not required to provide the information under this item.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended December 31, 2023, the Company issued 18,533,334 shares of its common stock for $110,000, in transactions that were exempt from registration under the Securities Act of 1933, as amended pursuant to Section 4(2) and/or Rule 506 promulgate under Regulation D. No gain or loss was recognized on the issuances. On April 5, 2023, the Company issued 5,000,000 shares to an investor at $0.005 per share for cash. On April 14, 2023, the Company issued 666,667 shares to an investor at $0.015 per share for cash. On April 27, 2023, the Company issued 5,000,000 shares to an investor at $0.005 per share for cash. On May 2, 2023, the Company issued 666,667 shares to an investor at $0.015 per share for cash. On May 4, 2023, the Company issued 2,000,000 shares to an investor at $0.005 per share for cash. On May 4, 2023, the Company issued 200,000 shares to an investor at $0.025 per share for cash. On May 24, 2023, the Company issued 5,000,000 shares to an investor at $0.005 per share for cash. On October 1, 2023, the Company issued 300,000 shares to an employee at $0.001 per share for services.

During the three months ended December 31, 2023, the Company issued 300,000 shares of its common stock. On October 1, 2023, the Company issued 300,000 shares to an employee at $0.001 per share for services.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

None

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

31.1	Certifications of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

31.2	Certifications of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

32.1	Certifications of Chief Executive Officer pursuant to 18 U.S.C. SEC. 1350 (Section 906 of Sarbanes-Oxley Act of 2002) +

32.2	Certifications of Chief Financial Officer pursuant to 18 U.S.C. SEC. 1350 (Section 906 of Sarbanes-Oxley Act of 2002) +

101.INS	Inline XBRL Instance Document *

101.SCH	Inline XBRL Taxonomy Extension Schema Document *

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document *

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document *

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document *

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document *

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EARTH SCIENCE TECH, INC.

Dated: February 20, 2024	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Chairman of the Board

Dated: February 20, 2024	By:	/s/ Gabrielle Schuster
		Gabrielle Schuster,
	Its:	Chief Financial Officer

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Giorgio R. Saumat, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Earth Science Tech, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under the Company’s supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report the Company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on the Company’s most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	EARTH SCIENCE TECH, INC.

Dated: February 20, 2024	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Chairman of the Board

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Gabrielle Schuster, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Earth Science Tech, Inc.;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report the company’s conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	EARTH SCIENCE TECH, INC.

Dated: February 20, 2024	By:	/s/ Gabrielle Schuster
		Gabrielle Schuster,
	Its:	Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Earth Science Tech, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Giorgio R. Saumat, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	EARTH SCIENCE TECH, INC.

Dated: February 20, 2024	By:	/s/ Giorgio R. Saumat
		Giorgio R. Saumat
	Its:	CEO and Chairman of the Board

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Earth Science Tech, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gabrielle Schuster, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

	EARTH SCIENCE TECH, INC.

Dated: February 20, 2024	By:	/s/ Gabrielle Schuster
		Gabrielle Schuster
	Its:	Chief Financial Officer

Cover	9 Months Ended
Cover	Dec. 31, 2023 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--03-31
Entity File Number	000-55000
Entity Registrant Name	EARTH SCIENCE TECH, INC.
Entity Central Index Key	0001538495
Entity Tax Identification Number	80-0931484
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	8950 SW 74th CT
Entity Address, Address Line Two	Suite 101
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33156
City Area Code	(305)
Local Phone Number	724-5684
Title of 12(b) Security	Common Stock $0.001 par value
Trading Symbol	ETST
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	314,850,730

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Current Assets:
Cash	$ 205,718	$ 35,756
Accounts Receivable (net allowance of $0 and $0 respectively)	112,826	0
Inventory	395,483	10,260
Total current assets	714,027	46,016
Other Assets:
Property and Equipment, net	121,339	143,213
Right of use asset, net	123,491	200,674
Intangible assets, net	122,318	137,819
Goodwill	2,164,480	2,164,480
Total other assets	2,531,628	2,646,186
Total Assets	3,245,655	2,692,202
Current Liabilities:
Accounts payable and accrued liabilities	643,434	517,137
Current portion of loans and obligations	30,492	604,767
Other Payables - Equipment Leases	68,050	117,193
Interest Payable	15,006	0
Current portion of operating lease obligations	68,184	68,188
Total current liabilities	825,166	1,307,285
Operating lease obligations; less current maturities	45,606	96,743
Loans and obligations; less current maturities	215,500	204,408
Total Liabilities	1,086,272	1,608,436
Stockholders’ (Deficit) Equity:
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 0 shares issued and outstanding as of December 31, 2023, and March 31, 2023, respectively	1,000	1,000
Common stock, par value $0.001 per share, 750,000,000 shares authorized; 314,850,730 and 282,612,083 shares issued and outstanding as of December 31, 2023, and March 31, 2023 respectively	314,852	282,612
Additional paid-in capital	31,766,199	31,303,138
Accumulated deficit	(29,922,668)	(30,502,984)
Total stockholders’ (Deficit)Equity	2,159,383	1,083,766
Total Liabilities and Stockholders’ (Deficit) Equity	$ 3,245,655	$ 2,692,202

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Statement of Financial Position [Abstract]
Accounts receivable net allowance	$ 0	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	0
Preferred stock, shares outstanding	1,000,000	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	314,850,730	282,612,083
Common stock, shares outstanding	314,850,730	282,612,083

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 3,790,112	$ 2,533	$ 5,937,766	$ 2,533
Cost of revenues	1,413,414	825	2,230,805	825
Gross Profit	2,376,698	1,708	3,706,961	1,708
Operating Expenses:
Compensation - officers	389,274	9,654	467,545	86,173
Officer compensation stock	0	0	0	4,500
Compensation – staff	181,524	0	361,558	0
General and administrative	1,496,708	5,599	2,012,669	161,540
Professional fees	27,135	22,233	97,181	31,433
Amortization & Depreciation	47,964	0	114,558	0
Marketing	3,062	4,200	19,586	4,200
Litigation Expense	0	0	0	512,725
Cost of legal proceedings	0	8,297	0	18,497
Total operating expenses	2,145,667	49,983	3,073,096	819,068
Income//(Loss) from operations	231,031	(48,275)	633,864	(817,360)
Other Income (Expenses)
Other Income	8,250	166,037	7,798	724,062
Interest expense	(13,838)	(18,321)	(61,347)	(29,565)
Note Payable Interest	0	0	0	(1,104)
Interest SBA Loan	0	(977)	0	(5,929)
Total other income (expenses)	(5,588)	146,739	(53,549)	687,464
Net Profit/(Loss) before income taxes	225,443	98,464	580,315	(129,896)
Income taxes	0	0	0	0
Net Profit/(Loss)	$ 225,443	$ 98,464	$ 580,315	$ (129,896)

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Mar. 31, 2023	$ 282,612	$ 1,000	$ 31,303,138	$ (30,502,984)	$ 1,083,766
Balance, shares at Mar. 31, 2023	282,611,083	1,000,000
Common stock issued for cash	$ 18,534		91,467		110,001
Common stock issued for services	$ 300				300
Common stock issued for services, shares	300,000
Common stock issued for Conversion on Note	$ 13,406		371,594		385,000
Net Profit/(Loss)				580,315	580,315
Common stock issued for cash, shares	18,533,334
Common stock issued for Conversion on Note, shares	13,406,313
Balance at Dec. 31, 2023	$ 314,852	$ 1,000	31,766,199	(29,915,885)	2,159,383
Balance, shares at Dec. 31, 2023	314,850,730	1,000,000
Balance at Sep. 30, 2023	$ 314,552	$ 1,000	31,766,199	(30,148,111)	1,933,640
Balance, shares at Sep. 30, 2023	314,550,730	1,000,000
Common stock issued for services	$ 300				300
Common stock issued for services, shares	300,000
Net Profit/(Loss)				225,443	225,443
Balance at Dec. 31, 2023	$ 314,852	$ 1,000	$ 31,766,199	$ (29,915,885)	$ 2,159,383
Balance, shares at Dec. 31, 2023	314,850,730	1,000,000

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net Profit/(Loss)	$ 580,315	$ (129,896)
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	300
Depreciation and amortization	114,558
Changes in operating assets and liabilities:
Deposits
Increase in Accounts receivable	(112,826)	(397,039)
Prepaid expenses and other current assets
Inventory	(385,223)
Stock issued for debt settlement		724,124
Other current liabilities	35,000
Accrued settlement	(310,947)	(565,663)
Accounts payable and accrued expenses	437,244	(300,780)
Net cash provided in operating activities	358,421	(669,254)
Cash flows from investing activities:
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock	18,534	316,500
Proceeds from Additional Paid In Capital	91,467
Increase/(Decrease) in Loans	(213,183)
Increase/(Decrease) in Other Payables	(34,136)
Increase/(Decrease) in Lease Liability	(51,141)
Proceeds from loans and notes		350,000
Net Cash Provided/Used by Financing Activities	(188,460)	666,500
Net increase (decrease) in cash and cash equivalents	169,962	(2,754)
Cash and cash equivalents at beginning of the period	35,756	26,942
Cash and cash equivalents at end of the period	205,718	$ 24,188
Non-Cash Transactions
Common stock issued on conversion of notes payable

Organization and Nature of Operations

9 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Nature of Operations

Note 1 — Organization and Nature of Operations

Summary of Significant Accounting Policies

9 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 — Summary of Significant Accounting Policies

Basis of presentation

Principles of consolidation

The accompanying consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries RxCompound, Peaks Curative, and ESF.

Use of estimates and assumptions

Carrying value, recoverability, and impairment of long-lived assets

Cash and cash equivalents

Related parties

The Company follows ASC 850 for the identification of related parties and disclosure of related party transactions.

Commitments and contingencies

Revenue recognition

Inventories

Cost of Revenues

Components of costs of sales include product and shipping costs to customers and any inventory adjustments.

Shipping and Handling Costs

The Company accounts shipping and handling costs to customers as cost of revenue.

Research and development

Income taxes

Net loss per common share

Cash flows reporting

Goodwill

Stock based compensation

Fair Value

Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs;

Level 2 — Significant other observable inputs that can be corroborated by observable market data; and

Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data.

The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items.

Property and equipment

Recently issued accounting pronouncements

We have considered the impact of the following pronouncements:

Intangible Assets

Reclassification

No restatement was made in comparative Consolidated Financial Statements. However, certain amounts from the prior year have been reclassified to conform to the current year presentation.

Going Concern

9 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

Note 3 — Going Concern

The condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Related Party Balances and Transactions

9 Months Ended

Dec. 31, 2023

Related Party Balances and Transactions

Note 4 - Related Party Balances and Transactions

Stockholders’ Equity

9 Months Ended

Dec. 31, 2023

Equity [Abstract]

Stockholders’ Equity

Note 5 – Stockholders’ Equity

Commitments and Contingencies

9 Months Ended

Dec. 31, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 6 — Commitments and Contingencies

Legal Proceedings

Employment and Consulting Agreements

Property and Equipment

9 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Property and Equipment

Note 7 — Property and Equipment

Schedule of Property And Equipment

	December 31, 2023			December 31, 2022
	For the Fiscal Quarter Ended December 31,
	December 31, 2023			December 31, 2022

Equipment – cost	$	150,082		$	-
Less: Accumulated depreciation		(28,743	)		-
Property and Equipment, Net	$	121,339		$	-

Depreciation expense for the fiscal quarters ended December 31, 2023, and December 31, 2022, was $99,056 and $0, respectively.

During the fiscal quarter ended December 31, 2023, there were no additions to the Property and Equipment.

Leases

9 Months Ended

Dec. 31, 2023

Leases

Leases

Note 8 — Leases

Supplemental balance sheet information related to leases were as follows:

	2023		2022
	For the Fiscal Quarter Ended December 31,
	2023		2022

Assets
Right of use asset, net	$	123,491	$	-

Operating lease liabilities
Current		68,184		-
Non-current		45,606		-
Total Lease Liabilities	$	113,790	$	-

The components of lease cost were as follows:

Schedule of Lease Cost

	2023		2022
	For the Fiscal Quarter Ended December 31,
	2023		2022

Depreciation	$	30,873	$	-
Interest on lease obligation		3,828		-
Total lease cost	$	34,701	$	-

Intangible Assets

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 9 — Intangible Assets

Intangible assets, consisted of the following:

Schedule of Intangible Assets

	2023			2022
	For the Fiscal Quarter Ended December 31,
	2023			2022

Telemedicine Property	$	17,806		$	17,806
Web Properties		19,323			-
Goodwill – historical basis		138,312			-
Accumulated Amortization		(53,123	)		-
Net Balance	$	122,318		$	17,806

GOODWILL

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL

NOTE 10- GOODWILL

SCHEDULE OF GOODWILL

	For the Fiscal Quarter Ended December 31,
	2023		2022
RxCompound and Peaks	$	2,164,480	$	-

Total	$	2,164,480	$	-

Accounts Payable and Accrued Expenses

9 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

Note 11 — Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	For the Fiscal Quarter Ended December 31, 2023

Accounts Payable (A)	$	515,337
Accrued Expenses (B)		128,097
Total	$	643,434

(A)

Accounts Payable

As of December 31, 2023, accounts payable included inventory under net 60 terms of $506,885, and other payables of $8,452.

(B)

Accrued Expenses

As of December 31, 2023, accrued expenses included accrued account management fee of $76,000, accrued payroll of $18,572 and other accrued expenses of $33,525.

Debts

9 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Debts

Note 12 — Debts

Notes payable and loans payable consisted of the following:

Schedule of Notes and Loans Payable

		For the Nine Months Ended December 31,
Name		2023		2022

SBA Loan Payable	(1)	$	215,500	$	113,115
Revolving Promissory Note Payable (Issa Note)	(2)		0.00		250,000
Convertible Promissory Note - Strongbow	(3)		0.00		220,000
Convertible Note Payable – Irrevocable Trust			0.00		350,000
Notes payable – related parties			0.00		110,363
Accrued Settlement			0.00		158,846
Equipment Finance			98,543		-
		$	314,043	$	1,202,524

(1) SBA Loan

Installment payments due within a year have been classified under current liabilities.

Both notes have been fully satisfied after December 31, 2023. Please refer to footnote,13 below, Subsequent Events, for additional information.

(2) Revolving Promissory Note –

(3) Convertible Promissory Note – Strongbow

Correction of Errors

9 Months Ended

Dec. 31, 2023

Accounting Changes and Error Corrections [Abstract]

Correction of Errors

Note 13 – Correction of Errors

Subsequent Events

9 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 14 — Subsequent Events

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).
Principles of consolidation	Principles of consolidation The accompanying consolidated financial statements include all the accounts of the Company and its wholly owned subsidiaries RxCompound, Peaks Curative, and ESF. The Company’s acquisition of RxCompound was consummated on November 8, 2022, along with Peaks Curative; however, RxCompound completed its PCAOB audit on February 3, 2023 (“Acquisition Date”). Operating results of subsidiaries have been consolidated according to their acquisition dates. No intercompany transactions and balances were identified.
Use of estimates and assumptions	Use of estimates and assumptions The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The areas requiring significant estimates are impairment of goodwill, provision for taxation, accrued liabilities, liabilities for legal matters, the determination of useful lives of depreciable and intangible assets, contingencies, and going concern assessment. The estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from those estimates.
Carrying value, recoverability, and impairment of long-lived assets	Carrying value, recoverability, and impairment of long-lived assets Company follows Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC’) 360 to evaluate its long-lived assets. The Company’s long-lived assets, which include property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company considers the following to be some examples of important indicators that may trigger an impairment review: (i) significant under-performance or losses of assets relative to expected historical or projected future operating results; (ii) significant changes in the manner or use of assets or in the Company’s overall strategy with respect to the manner or use of the acquired assets or changes in the Company’s overall business strategy; (iii) significant negative industry or economic trends; (iv) increased competitive pressures; (v) a significant decline in the Company’s stock price for a sustained period of time; and (vi) regulatory changes. The Company evaluates assets for potential impairment indicators at least annually and more frequently upon the occurrence of such events. Impairment of assets, if any, are included in operating expenses.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents include all highly liquid debt instruments with original maturities of three months or less which are not securing any corporate obligations. As of December 31, 2023, and March 31, 2023, the Company held a cash balance of $205,718 and $35,756, respectively.
Related parties	Related parties The Company follows ASC 850 for the identification of related parties and disclosure of related party transactions. Pursuant to this ASC related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.
Commitments and contingencies	Commitments and contingencies The Company follows ASC 450 to account for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. This may result in contingent liabilities that are required to be accrued or disclosed in the financial statements. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.
Revenue recognition	Revenue recognition Revenue is recognized when the Company transfers control of its products to the customer, which typically occurs at a point-in-time, either upon shipment or delivery. Substantially all of the Company’s net revenues relate to products which are transferred to the customer at a point-in-time.
Inventories	Inventories The Company has its inventories stated at the lower of cost (on first in, first out (FIFO) method) or market value basis. A reserve is established if necessary to reduce excess or obsolete inventories to their realizable value. The stated cost consists of bulk ingredients used to compound finished products as well as finished products. Reserves, if necessary, are recorded to reduce inventory to market value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items. These assumptions are evaluated annually and are based on the Company’s business plan and from feedback from customers and the product development team.
Cost of Revenues	Cost of Revenues Components of costs of sales include product and shipping costs to customers and any inventory adjustments.
Shipping and Handling Costs	Shipping and Handling Costs The Company accounts shipping and handling costs to customers as cost of revenue.
Research and development	Research and development Research and development costs are expensed as incurred. The Company’s research and development expenses relate to its engineering activities, which consist of the design and development of new products for specific customers, as well as the design and engineering of new or redesigned products for the industry in general.
Income taxes	Income taxes The Company accounts for income taxes under ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. This first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes. The Company recognizes a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2023, the Company has not recorded any unrecognized tax benefits. Interest and penalties related to liabilities for uncertain tax positions will be charged to interest and operating expenses, respectively. The Company has net operating loss carryforwards (NOL) for income tax purposes of approximately $1,600,281. This loss is allowed to be offset against future income until the year 2039 when the NOL’s will expire. The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the substantial losses incurred through March 31, 2022. The change in the valuation allowance for the six months ended December 31, 2023, and 2022, was an increase of $0 and $0, respectively. Internal Revenue Code Section 382 (“Section 382”) imposes limitations on the availability of a company’s net operating losses after certain ownership changes occur. The Section 382 limitation is based upon certain conclusions pertaining to the dates of ownership changes and the value of the Company on the dates of the ownership changes. It was determined that an ownership change occurred in October 2013 and March 2014. The amount of the Company’s net operating losses incurred prior to the ownership changes are limited based on the value of the Company on the date of the ownership change. Management has not determined the amount of net operating losses generated prior to the ownership change available to offset taxable income after the ownership change.
Net loss per common share	Net loss per common share The Company follows ASC 260 to account for earnings per share. Basic earnings per common share calculations are determined by dividing net results from operations by the weighted average number of shares of common stock outstanding during the year. Diluted loss per common share calculations is determined by dividing net results from operations by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. For the nine months ended December 31, 2023, shares issuable upon conversion of convertible notes were anti-dilutive. As such, their effect has not been included in the calculation of diluted net loss per share. No dilutive common shares in the comparative year.
Cash flows reporting	Cash flows reporting The Company follows ASC 230 to report cash flows. This standard classifies cash receipts and payments according to whether they stem from operating, investing, or financing activities and provides definitions of each category, and uses the indirect or reconciliation method (“Indirect method”) as defined by this standard to report net cash flow from operating activities by adjusting net income to reconcile it to net cash flow from operating activities by removing the effects of (a) all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments and (b) all items that are included in net income that do not affect operating cash receipts and payments. The Company reports separately information about investing and financing activities not resulting in cash receipts or payments in the period pursuant this standard.
Goodwill	Goodwill Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Goodwill is reviewed for impairment on an annual basis, or more frequently if events or changes in circumstances indicate that the carrying amount of goodwill may be impaired. In conducting its annual impairment test, the Company first reviews qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. If factors indicate that the fair value of the reporting unit is less than its carrying amount, the Company performs a quantitative assessment and the fair value of the reporting unit is determined by analyzing the expected present value of future cash flows. If the carrying value of the reporting unit continues to exceed its fair value, the fair value of the reporting unit’s goodwill is calculated and an impairment loss equal to the excess is recorded. As of December 31, 2023, the Company recognized goodwill on the acquisition of its wholly owned subsidiaries; RxCompound and Peaks.
Stock based compensation	Stock based compensation The Company applies the fair value method of ASC 718, Compensation-Stock Compensation, in accounting for its stock-based compensation. These standards state that compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period, if any. The Company uses the Black-Scholes option pricing model to determine the fair value of its stock, stock option and warrant issuance. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price, as well as assumptions regarding a few complex and subjective variables. These variables include the Company’s expected stock price, volatility over the term of the awards, actual employee exercise behaviors, risk-free interest rate and expected dividends. The company has no stock-based commitments outstanding as of December 31, 2023, and 2022.
Fair Value	Fair Value FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories: Level 1 — Quoted market prices for identical assets or liabilities in active markets or observable inputs; Level 2 — Significant other observable inputs that can be corroborated by observable market data; and Level 3 — Significant unobservable inputs that cannot be corroborated by observable market data. The carrying amounts of cash, accounts payable and other liabilities, accrued expenses and settlement payable approximate fair value because of the short-term nature of these items. The fair value of the Company’s debt approximated the carrying value of the Company’s debt as of December 31, 2023, and December 31, 2022. Factors that the Company considered when estimating the fair value of its debt included market conditions, liquidity levels in the private placement market, variability in pricing from multiple lenders and terms of debt.
Property and equipment	Property and equipment Property and equipment are stated at cost net of accumulated depreciation. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation on equipment is charged using a straight-line method over the estimated useful life of 5 years.
Recently issued accounting pronouncements	Recently issued accounting pronouncements We have considered the impact of the following pronouncements: In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which requires entities to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers (“ASC 606”). The update will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the acquiree immediately before the acquisition date rather than at fair value. ASU 2021-08 was effective on a prospective basis for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted ASU 2021-08 effective January 1, 2023, and will apply the guidance to subsequent acquisitions. The adoption of ASU 2021-08 did not have an impact on the Company’s consolidated financial statements because the Company did not acquire a business during the three and nine months ended December 31, 2023. The FASB recently issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, which requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities for fiscal years beginning after December 15, 2021, with early adoption permitted (for “emerging growth companies” beginning after December 15, 2023). The Company has assessed the impact this standard will have on the Company’s consolidated financial statements. No material adjustments were required.
Intangible Assets	Intangible Assets Intangible assets consist of Peaks telemedicine property, the Company’s web properties and goodwill recognized by RxCompound which is presented on the historical basis at date of acquisition by the Company. Prior to the acquisition, RxCompound, elected to amortize goodwill as an intangible asset on a straight-line basis over 10 years. All other Intangible assets with finite lives are amortized over the estimated useful life of five years. These assets are evaluated for impairment at least on an annual basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We assess recoverability by determining whether the carrying value of such assets will be recovered through the undiscounted expected future cash flows. If the future undiscounted cash flows are less than the carrying amount of these assets, we recognize an impairment loss based on the excess of the carrying amount over the fair value of the assets.
Reclassification	Reclassification No restatement was made in comparative Consolidated Financial Statements. However, certain amounts from the prior year have been reclassified to conform to the current year presentation.

Property and Equipment (Tables)

9 Months Ended

Dec. 31, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property And Equipment

	December 31, 2023			December 31, 2022
	For the Fiscal Quarter Ended December 31,
	December 31, 2023			December 31, 2022

Equipment – cost	$	150,082		$	-
Less: Accumulated depreciation		(28,743	)		-
Property and Equipment, Net	$	121,339		$	-

Leases (Tables)

9 Months Ended

Dec. 31, 2023

Leases

Schedule of Supplemental Balance Sheet Related to Leases

Supplemental balance sheet information related to leases were as follows:

	2023		2022
	For the Fiscal Quarter Ended December 31,
	2023		2022

Assets
Right of use asset, net	$	123,491	$	-

Operating lease liabilities
Current		68,184		-
Non-current		45,606		-
Total Lease Liabilities	$	113,790	$	-

Schedule of Lease Cost

The components of lease cost were as follows:

Schedule of Lease Cost

	2023		2022
	For the Fiscal Quarter Ended December 31,
	2023		2022

Depreciation	$	30,873	$	-
Interest on lease obligation		3,828		-
Total lease cost	$	34,701	$	-

Intangible Assets (Tables)

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets, consisted of the following:

Schedule of Intangible Assets

	2023			2022
	For the Fiscal Quarter Ended December 31,
	2023			2022

Telemedicine Property	$	17,806		$	17,806
Web Properties		19,323			-
Goodwill – historical basis		138,312			-
Accumulated Amortization		(53,123	)		-
Net Balance	$	122,318		$	17,806

GOODWILL (Tables)

9 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

SCHEDULE OF GOODWILL

	For the Fiscal Quarter Ended December 31,
	2023		2022
RxCompound and Peaks	$	2,164,480	$	-

Total	$	2,164,480	$	-

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Dec. 31, 2023

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consisted of the following:

	For the Fiscal Quarter Ended December 31, 2023

Accounts Payable (A)	$	515,337
Accrued Expenses (B)		128,097
Total	$	643,434

Debts (Tables)

9 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Schedule of Notes and Loans Payable

Notes payable and loans payable consisted of the following:

Schedule of Notes and Loans Payable

		For the Nine Months Ended December 31,
Name		2023		2022

SBA Loan Payable	(1)	$	215,500	$	113,115
Revolving Promissory Note Payable (Issa Note)	(2)		0.00		250,000
Convertible Promissory Note - Strongbow	(3)		0.00		220,000
Convertible Note Payable – Irrevocable Trust			0.00		350,000
Notes payable – related parties			0.00		110,363
Accrued Settlement			0.00		158,846
Equipment Finance			98,543		-
		$	314,043	$	1,202,524

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Mar. 31, 2023
Accounting Policies [Abstract]
Cash	$ 205,718		$ 35,756
Unrecognized tax benefits	0
Net operating loss carryforwards	1,600,281
Valuation allowance	$ 0	$ 0

Going Concern (Details Narrative) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 29,922,668	$ 30,502,984

Stockholders’ Equity (Details Narrative) - USD ($)	3 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Nov. 28, 2023	Nov. 27, 2023	Mar. 31, 2023
Equity [Abstract]
Number of shares issued	300,000	62,600,000
Value of stock issued	$ 0	$ 316,500
Number of shares issued for debt settlements	0	136,312,440
Value of stock issued for debt settlements	$ 0	$ 724,124
Common stock, shares authorized	750,000,000		350,000,000	750,000,000	750,000,000

Commitments and Contingencies (Details Narrative) - shares		3 Months Ended
	Aug. 01, 2023	Dec. 31, 2023	Dec. 31, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of shares issued		300,000	62,600,000
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Executive compensation monthly revenue percentage maximum		21.00%
President [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Executive compensation monthly revenue percentage maximum		10.50%
Shibu John [Member] \| Employment Agreement [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of shares issued	300,000

Schedule of Property And Equipment (Details) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Property, Plant and Equipment [Line Items]
Less: Accumulated depreciation	$ (28,743)
Property and Equipment, Net	121,339	$ 143,213
Equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment – cost	$ 150,082

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 99,056

Schedule of Supplemental Balance Sheet Related to Leases (Details) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Leases
Right of use asset, net	$ 123,491	$ 200,674
Current	68,184	68,188
Non-current	45,606	$ 96,743
Total Lease Liabilities	$ 113,790

Schedule of Lease Cost (Details) - USD ($)	3 Months Ended
Schedule of Lease Cost (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Leases
Depreciation	$ 30,873
Interest on lease obligation	3,828
Total lease cost	$ 34,701

Leases (Details Narrative)	1 Months Ended
Leases (Details Narrative)	Jun. 30, 2022 USD ($)
Leases
Lease payments	$ 7,057
Lum sum lease payment	$ 40,000
Renewal lease term	3 years

Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (53,123)
Net Balance	122,318	17,806
Telemedicine Platform [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill – historical basis	17,806	17,806
Web Domain [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill – historical basis	19,323
Goodwill Historical Basis [Member]
Finite-Lived Intangible Assets [Line Items]
Goodwill – historical basis	$ 138,312

SCHEDULE OF GOODWILL (Details) - USD ($)	Dec. 31, 2023	Mar. 31, 2023
Goodwill	$ 2,164,480	$ 2,164,480
Rx Compound Storecom LLC and Peaks Curative LLC [Member]
Goodwill	$ 2,164,480

GOODWILL (Details Narrative)	Nov. 08, 2020
Rx Compound Store.com LLC And Peaks Curative LLC [Member]
Restructuring Cost and Reserve [Line Items]
Acquired percentage	100.00%

Schedule of Accounts Payable and Accrued Expenses (Details)	Dec. 31, 2023 USD ($)
Payables and Accruals [Abstract]
Accounts Payable (A)	$ 515,337
Accrued Expenses (B)	128,097
Total	$ 643,434

Accounts Payable and Accrued Expenses (Details Narrative)	Dec. 31, 2023 USD ($)
Long-Term Purchase Commitment [Line Items]
Accounts payable	$ 515,337
Other notes payable	8,452
Management fee payable	76,000
Accrued payroll	18,572
Other expenses	33,525
Inventories [Member]
Long-Term Purchase Commitment [Line Items]
Accounts payable	$ 506,885

Schedule of Notes and Loans Payable (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2021	Apr. 01, 2021	Jul. 27, 2020
Short-Term Debt [Line Items]
Total debt	$ 314,043	$ 1,202,524
SBA Loan Payable [Member]
Short-Term Debt [Line Items]
Total debt	215,500	113,115		$ 108,700	$ 106,800
Revolving Promissory Note Payable [Member]
Short-Term Debt [Line Items]
Total debt	0.00	250,000	$ 250,000
Convertible Promissory Note Strongbow [Member]
Short-Term Debt [Line Items]
Total debt	0.00	220,000
Convertible Note Payable Irrevocable Trust [Member]
Short-Term Debt [Line Items]
Total debt	0.00	350,000
Promissory Note Payable Two [Member]
Short-Term Debt [Line Items]
Total debt	0.00	110,363
Accrued Settlement [Member]
Short-Term Debt [Line Items]
Total debt	0.00	158,846
Equipment Finance [Member]
Short-Term Debt [Line Items]
Total debt	$ 98,543

Debts (Details Narrative) - USD ($)									1 Months Ended
Debts (Details Narrative) - USD ($)	Jan. 01, 2024	Sep. 30, 2023	Sep. 01, 2023	May 29, 2023	Apr. 01, 2022	Jan. 28, 2022	Apr. 01, 2021	Jul. 27, 2020	Sep. 30, 2023	Feb. 09, 2024	Jan. 19, 2024	Dec. 31, 2023	Dec. 31, 2022	Aug. 31, 2021
Short-Term Debt [Line Items]
Loan amount												$ 314,043	$ 1,202,524
Debt Instrument, Maturity Date, Description				Strongbow Advisors’ accrued settlement of $220,000 with a maturity date of May 29, 2023, was amended on the maturity date, having its payment terms rescheduled.
SBA Loan Payable [Member]
Short-Term Debt [Line Items]
Loan amount							$ 108,700	$ 106,800				215,500	113,115
Interest rate							3.75%	3.75%
Debt instrument periodic payment							$ 530.00	$ 521.00
SBA Loan Payable [Member] \| Subsequent Event [Member]
Short-Term Debt [Line Items]
Loan amount										$ 106,800	$ 108,700
Revolving Promissory Note Payable [Member]
Short-Term Debt [Line Items]
Loan amount												$ 0.00	$ 250,000	$ 250,000
Interest rate														5.00%
Debt instrument periodic payment									$ 109,167
Debt instrument periodic principal payment					$ 200,000	$ 50,000
Revolving Promissory Note Payable [Member] \| Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment	$ 160,000
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Debt instrument periodic payment			$ 5,000
Debt instrument face amount				$ 220,000
Payments of debt issuance cost				$ 15,000
Debt instrument pre-payment of discounts			$ 70,000
Debt instrument increase and decrease			10.00%
Debt instrument prepayment discount		$ 118,000

Correction of Errors (Details Narrative)	9 Months Ended
Correction of Errors (Details Narrative)	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Error correction description	As a consequence, the total assets were understated by $13,860 and the net loss was overstated by the same amount. The Company is in the process of correcting the errors by restating each of the affected financial statement line items in the consolidated financial statements and related financial statement footnotes in an amended 10-K/A for the year-ended March 31, 2023. The error resulted in additional amortization of $10,374 for the current nine months ended December 31, 2023. The amount of the error is less than one (1) percent of revenue resulting is no material impact on the Company’s consolidated financial statements as of December 31, 2023

Subsequent Events (Details Narrative) - USD ($)	Feb. 09, 2024	Jan. 19, 2024	Dec. 31, 2023	Dec. 31, 2022	Apr. 01, 2021	Jul. 27, 2020
Subsequent Event [Line Items]
Loan amount			$ 314,043	$ 1,202,524
SBA Loan Payable [Member]
Subsequent Event [Line Items]
Loan amount			$ 215,500	$ 113,115	$ 108,700	$ 106,800
Subsequent Event [Member] \| SBA Loan Payable [Member]
Subsequent Event [Line Items]
Loan amount	$ 106,800	$ 108,700

Grafico Azioni Innovator US Equity Ultr... (AMEX:UNOV)
Storico
Da Dic 2024 a Gen 2025

Clicca qui per i Grafici di Innovator US Equity Ultr...

Grafico Azioni Innovator US Equity Ultr... (AMEX:UNOV)
Storico
Da Gen 2024 a Gen 2025

UNOV Innovator US Equity Ultra Buffer ETF November

Notizie Innovator US Equity Ultra Buffer ETF November - UNOV

La tua Cronologia

Più Attivi

Toplist

UNOV Innovator US Equity Ultra Buffer ETF November

Notizie Innovator US Equity Ultra Buffer ETF November - UNOV

La tua Cronologia